John Duncan Higgons - Net Worth and Insider Trading
John Duncan Higgons Net Worth
The estimated net worth of John Duncan Higgons is at least $2 Million dollars as of 2024-05-15. John Duncan Higgons is the COO of Agios Pharmaceuticals Inc and owns about 61,835 shares of Agios Pharmaceuticals Inc (AGIO) stock worth over $2 Million. John Duncan Higgons is also the Director of Jounce Therapeutics Inc and owns about 9,713 shares of Jounce Therapeutics Inc (JNCE) stock worth over $18,260. Details can be seen in John Duncan Higgons's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that John Duncan Higgons has not made any transactions after 2021-04-15 and currently still holds the listed stock(s).
Transaction Summary of John Duncan Higgons
John Duncan Higgons Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, John Duncan Higgons owns 2 companies in total, including Jounce Therapeutics Inc (JNCE) , and Agios Pharmaceuticals Inc (AGIO) .
Click here to see the complete history of John Duncan Higgons’s form 4 insider trades.
Insider Ownership Summary of John Duncan Higgons
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| JNCE | Jounce Therapeutics Inc | 2021-04-15 | director |
| AGIO | Agios Pharmaceuticals Inc | 2015-12-15 | 10 percent owner & Chief Operating Officer |
John Duncan Higgons Latest Holdings Summary
John Duncan Higgons currently owns a total of 2 stocks. Among these stocks, John Duncan Higgons owns 61,835 shares of Agios Pharmaceuticals Inc (AGIO) as of December 15, 2015, with a value of $2 Million and a weighting of 99.16%. John Duncan Higgons also owns 9,713 shares of Jounce Therapeutics Inc (JNCE) as of April 15, 2021, with a value of $18,260 and a weighting of 0.84%.
Latest Holdings of John Duncan Higgons
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| AGIO | Agios Pharmaceuticals Inc | 2015-12-15 | 61,835 | 34.99 | 2,163,607 |
| JNCE | Jounce Therapeutics Inc | 2021-04-15 | 9,713 | 1.88 | 18,260 |
Holding Weightings of John Duncan Higgons
John Duncan Higgons Form 4 Trading Tracker
According to the SEC Form 4 filings, John Duncan Higgons has made a total of 0 transactions in Agios Pharmaceuticals Inc (AGIO) over the past 5 years. The most-recent trade in Agios Pharmaceuticals Inc is the sale of 20,000 shares on December 15, 2015, which brought John Duncan Higgons around $1 Million.
According to the SEC Form 4 filings, John Duncan Higgons has made a total of 5 transactions in Jounce Therapeutics Inc (JNCE) over the past 5 years, including 0 buys and 5 sells. The most-recent trade in Jounce Therapeutics Inc is the sale of 200 shares on April 15, 2021, which brought John Duncan Higgons around $2,000.
Insider Trading History of John Duncan Higgons
- 1
John Duncan Higgons Trading Performance
GuruFocus tracks the stock performance after each of John Duncan Higgons's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by John Duncan Higgons is 66.53%. GuruFocus also compares John Duncan Higgons's trading performance to market benchmark return within the same time period. The performance of stocks bought by John Duncan Higgons within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how John Duncan Higgons's insider trading performs compared to the benchmark.
Performance of John Duncan Higgons
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 24.34 | | | | | |
| Relative Return to S&P 500(%) | 19.23 | | | | | |
John Duncan Higgons Ownership Network
John Duncan Higgons Owned Company Details
What does Jounce Therapeutics Inc do?
Who are the key executives at Jounce Therapeutics Inc?
John Duncan Higgons is the director of Jounce Therapeutics Inc. Other key executives at Jounce Therapeutics Inc include 10 percent owner Concentra Merger Sub, Inc. , 10 percent owner Concentra Biosciences, Llc , and director & CEO and President Richard /ca/ Murray .
Jounce Therapeutics Inc (JNCE) Insider Trades Summary
Over the past 18 months, John Duncan Higgons made no insider transaction in Jounce Therapeutics Inc (JNCE). Other recent insider transactions involving Jounce Therapeutics Inc (JNCE) include a net sale of 84,298 shares made by Richard /ca/ Murray , a net purchase of 85,987 shares made by Kevin C Tang , and a net sale of 16,634 shares made by Hugh M Cole .
In summary, during the past 3 months, insiders sold 0 shares of Jounce Therapeutics Inc (JNCE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 124,313 shares of Jounce Therapeutics Inc (JNCE) were sold and 85,987 shares were bought by its insiders, resulting in a net sale of 38,326 shares.
Jounce Therapeutics Inc (JNCE)'s detailed insider trading history can be found in Insider Trading Tracker table.
Jounce Therapeutics Inc Insider Transactions
John Duncan Higgons Mailing Address
Above is the net worth, insider trading, and ownership report for John Duncan Higgons. You might contact John Duncan Higgons via mailing address: C/o Agios Pharmaceuticals, Inc., 38 Sidney Street, 2nd Floor, Cambridge Ma 02139.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
